Trospium Chloride
Sponsors
Allergan, NICHD Pelvic Floor Disorders Network, University of North Carolina, Chapel Hill, Karuna Therapeutics, Mansoura University
Conditions
Accidental FallsCognitive FunctionElderlyHealthy VolunteersMental CompetencyOveractive BladderPharmacokineticsQuality of Life
Early Phase 1
Phase 1
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
CompletedNCT02831231
Start: 2016-09-07End: 2016-10-28Updated: 2017-04-19
A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants
RecruitingNCT07063342
Start: 2025-06-27End: 2026-08-15Target: 72Updated: 2025-12-19
Phase 3
Phase 4
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial
CompletedNCT00863551
Start: 2009-04-30End: 2009-08-31Updated: 2016-02-26
Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
CompletedNCT01089751
Start: 2010-03-31End: 2012-06-30Updated: 2013-09-26
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
CompletedNCT01178827
Start: 2010-08-31End: 2011-03-31Updated: 2016-02-26
The Effect of Anticholinergics on Cognitive Function in the Elderly
CompletedNCT01922115
Start: 2013-06-30End: 2015-06-30Updated: 2017-03-22